Journal
IMMUNOTARGETS AND THERAPY
Volume 7, Issue -, Pages 35-49Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/ITT.S134842
Keywords
cancer; melanoma; therapy; targets
Categories
Funding
- Portuguese Foundation for Science and Technology through a Post-Doc [SFRH/BPD/85249/2012]
- FCT
- FEDER - Fundo Europeu de Desenvolvimento Regional funds through COMPETE - Operational Programme for Competitiveness and Internationalisation (POCI), Portugal
- Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Inovacao [POCI-01-0145-FEDER-007274]
- Norte - Programa Operacional Regional do Norte
- European Regional Development Fund (ERDF) through the Operational Programme for Competitiveness and Internationalisation - COMPETE
- Portuguese national funds via FCT - Fundacao para a Ciencia e a Tecnologia [POCI-01-0145-FEDER-016390]
- [NORTE-01-0145-FEDER-000029]
Ask authors/readers for more resources
Melanoma represents the most aggressive and the deadliest form of skin cancer. Current therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy, immunotherapy, biochemotherapy, and targeted therapy. The therapeutic strategy can include single agents or combined therapies, depending on the patient's health, stage, and location of the tumor. The efficiency of these treatments can be decreased due to the development of diverse resistance mechanisms. New therapeutic targets have emerged from studies of the genetic profile of melanocytes and from the identification of molecular factors involved in the pathogenesis of the malignant transformation. In this review, we aim to survey therapies approved and under evaluation for melanoma treatment and relevant research on the molecular mechanisms underlying melanomagenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available